Eligibility for finerenone in real-world patients with diabetes and chronic kidney disease: Insights from the FIDELITY pooled analysis

IF 2 4区医学 Q2 UROLOGY & NEPHROLOGY

Nefrologia Pub Date : 2025-06-01 DOI:10.1016/j.nefro.2025.01.001

Alberto Esteban-Fernández , Carlos de Blas-Ruiz , Maitane Fernández-Ustoa , Elena Gabaldón-Perucha , Beatriz López-Gómez , Guadalupe Ruiz-Martín

引用次数: 0

查看原文本刊更多论文

现实世界中糖尿病和慢性肾脏疾病患者使用芬尼酮的资格：来自FIDELITY汇总分析的见解

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nefrologia 医学-泌尿学与肾脏学

CiteScore

3.40

自引率

7.70%

发文量

148

审稿时长

47 days

期刊介绍： Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages.